<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4</volume><submitter>Neven P</submitter><journal>Translational breast cancer research : a journal focusing on translational research in breast cancer</journal><pagination>31</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11093079</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Navigating next-generation HR&lt;sup>+&lt;/sup>/HER2&lt;sup>-&lt;/sup> metastatic breast cancer therapies: a critical commentary on abemaciclib &lt;i>vs.&lt;/i> tucidinostat after palbociclib progression.</pubmed_title><pmcid>PMC11093079</pmcid><pubmed_authors>Van Houdt M</pubmed_authors><pubmed_authors>Dullens L</pubmed_authors><pubmed_authors>Neven P</pubmed_authors><pubmed_authors>Deblander A</pubmed_authors><pubmed_authors>Wildiers H</pubmed_authors><pubmed_authors>Han S</pubmed_authors><pubmed_authors>Van Herck Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Navigating next-generation HR&lt;sup>+&lt;/sup>/HER2&lt;sup>-&lt;/sup> metastatic breast cancer therapies: a critical commentary on abemaciclib &lt;i>vs.&lt;/i> tucidinostat after palbociclib progression.</name><description/><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-06-03T03:50:43.851Z</modification><creation>2026-04-24T03:09:31.959Z</creation></dates><accession>S-EPMC11093079</accession><cross_references><pubmed>38751459</pubmed><doi>10.21037/tbcr-23-41</doi></cross_references></HashMap>